CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study - PubMed (original) (raw)
doi: 10.1016/S1470-2045(09)70186-X. Epub 2009 Aug 3.
Paolo Bianchi, Elena Miranda, Emanuela Balladore, Veronica Pacetti, Fabio Grizzi, Paola Allavena, Valter Torri, Alessandro Repici, Armando Santoro, Alberto Mantovani, Massimo Roncalli, Alberto Malesci
Affiliations
- PMID: 19656725
- DOI: 10.1016/S1470-2045(09)70186-X
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study
Luigi Laghi et al. Lancet Oncol. 2009 Sep.
Abstract
Background: The density of tumour-infiltrating lymphocytes (TIL) has been proposed as an independent predictor of outcome in patients with colorectal cancer. However, the relative roles of TIL density, nodal status, and microsatellite instability (MSI) in predicting tumour progression to metachronous metastasis remain to be elucidated. The aim of this study was to assess the relationship between the density of CD3+ TIL and the postsurgical occurrence of distant-organ metastases in a large series of patients with deeply invading and MSI-typed colorectal cancer.
Methods: Per cent areas of immunoreactivity due to CD3+ TIL at the invasive margin of the tumour (CD3+ TIL(IM)) were measured by computer-assisted image analysis in 286 tissue specimens from pT3 or pT4 MSI-tested colorectal cancer. Tissue samples were taken from consecutive patients who underwent resection at the IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy, from January, 1997, to November, 2004, for colorectal cancer with no evidence of metastasis at diagnosis. Occurrence of metachronous metastasis, disease-specific survival (DSS), and disease-free survival (DFS), were assessed retrospectively in relation to per cent immunoreactivity.
Findings: CD3+ TIL(IM) density was higher in MSI colorectal cancer than in mismatch repair-system-proficient tumours (6.53%vs 2.19%; p<0.0001). At Cox analysis, higher CD3+ TIL(IM) densities, colonic site, and absence of nodal involvement were significantly associated with a lower risk of metachronous metastasis, but only the interaction between CD3+ TIL(IM) density and N-stage was significant on multivariate analysis (p=0.002). On separate analysis of node-negative colorectal cancer, increasing percentage of CD3+ immunoreactive area progressively reduced the risk of metachronous metastasis (<1%, reference; 1-5%, HR 0.28, 95% CI 0.10-0.81, p=0.02; >5%, 0.06, 0.01-0.48, p=0.008). Conversely, no significant association was seen between CD3+ immunoreactive area and risk of metachronous metastasis in node-positive colorectal cancer. Accordingly, CD3+ TIL(IM) density was associated with a better DSS (p=0.01) and DFS (p=0.006) only in patients with node-negative colorectal cancer. In primary tumours that had progressed to metachronous metastasis, stage III tumours had higher CD3+ TIL(IM) densities than stage II tumours (p=0.0004).
Interpretation: Metachronous metastases are unlikely to arise from node-negative colorectal cancers with a high-density CD3+ TIL(IM), whereas high densities of CD3+ TIL(IM) are not associated with the absence of postsurgical metastasis in patients with node-positive colorectal cancer. Our data suggest that densities of CD3+ TIL(IM) cannot be used as an independent predictor of clinical outcome in patients with stage III colorectal cancer and, at least for now, the tumour-node-metastasis classification should remain the preferred prognostic system. Our findings are consistent with a relationship between nodal involvement and tumour immunoevasion.
Funding: MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca), Target Project Oncologia 2006, and Alleanza Contro il Cancro.
Comment in
- Lymphocyte infiltration and prognosis in colorectal cancer.
Kloor M. Kloor M. Lancet Oncol. 2009 Sep;10(9):840-1. doi: 10.1016/S1470-2045(09)70245-1. Lancet Oncol. 2009. PMID: 19717085 No abstract available.
Similar articles
- The clinical utility of the local inflammatory response in colorectal cancer.
Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. Richards CH, et al. Eur J Cancer. 2014 Jan;50(2):309-19. doi: 10.1016/j.ejca.2013.09.008. Epub 2013 Oct 5. Eur J Cancer. 2014. PMID: 24103145 - Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.
Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F. Di Caro G, et al. Clin Cancer Res. 2014 Apr 15;20(8):2147-58. doi: 10.1158/1078-0432.CCR-13-2590. Epub 2014 Feb 12. Clin Cancer Res. 2014. PMID: 24523438 - The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.
Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. Curtis NJ, et al. Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Eur J Surg Oncol. 2012. PMID: 22721580 Review. - Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM, Pandeya N, Cummings MC, Walsh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-Smith GL. Michael-Robinson JM, et al. J Pathol. 2003 Sep;201(1):46-54. doi: 10.1002/path.1406. J Pathol. 2003. PMID: 12950016 - The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer.
Roxburgh CS, McMillan DC. Roxburgh CS, et al. Cancer Treat Rev. 2012 Aug;38(5):451-66. doi: 10.1016/j.ctrv.2011.09.001. Epub 2011 Sep 25. Cancer Treat Rev. 2012. PMID: 21945823 Review.
Cited by
- UEG Week 2020 Poster Presentations.
[No authors listed] [No authors listed] United European Gastroenterol J. 2020 Oct;8(8_suppl):144-887. doi: 10.1177/2050640620927345. United European Gastroenterol J. 2020. PMID: 33043826 Free PMC article. No abstract available. - Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results.
Sofra M, Fei PC, Fabrizi L, Marcelli ME, Claroni C, Gallucci M, Ensoli F, Forastiere E. Sofra M, et al. J Exp Clin Cancer Res. 2013 Feb 3;32(1):6. doi: 10.1186/1756-9966-32-6. J Exp Clin Cancer Res. 2013. PMID: 23374147 Free PMC article. Clinical Trial. - Prognostic significance of the Naples prognostic score in colorectal cancer patients undergoing curative resection: a propensity score matching analysis.
Sugimoto A, Fukuoka T, Shibutani M, Kasashima H, Kitayama K, Ohira M, Maeda K. Sugimoto A, et al. BMC Gastroenterol. 2023 Mar 25;23(1):88. doi: 10.1186/s12876-023-02722-6. BMC Gastroenterol. 2023. PMID: 36966294 Free PMC article. - The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors.
Donadon M, Lleo A, Di Tommaso L, Soldani C, Franceschini B, Roncalli M, Torzilli G. Donadon M, et al. Front Oncol. 2018 May 28;8:181. doi: 10.3389/fonc.2018.00181. eCollection 2018. Front Oncol. 2018. PMID: 29892573 Free PMC article. Review. - Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis.
Pancione M, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, Ceccarelli M, Colantuoni V. Pancione M, et al. J Immunol Res. 2014;2014:686879. doi: 10.1155/2014/686879. Epub 2014 Jan 16. J Immunol Res. 2014. PMID: 24741617 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical